Appendix 4C – quarterly
Invitrocue launches world’s first commercial Personalised Cancer Screening Service: Onco-PDO™
Half Yearly Report and Accounts
Invitrocue secures grant from Northern Ireland to commercialise Onco-PDO
Change of Director’s Interest Notice – Jamie Khoo
Change of Director’s Interest Notice – Steven Fang
Change of Director’s Interest Notice – Hanry Yu
Initial Director’s Interest Notice
Appointment of non-executive director
Appendix 4C & quarterly business update
Invitrocue further validates its Onco-PDO technology platform through the successful growth of 14 liver cancer organoids
Proposed Issue of Securities
Results of Annual General Meeting
2017 AGM Presentation
Proposed issue of securities
Highlights for the quarter ending September 2017
Appendix 4C – Quarterly Report
Notice of Annual General Meeting and Explanatory Statement
Annual Report For The Period Ended 30 June 20167
Invitrocue announces appointments to the management team
Preliminary Final Report: Download here.
IVQ receives award from Singapore government IP office
Appendix 4C – Quarterly Report and Business Update Investor Call
L-R: Dr Benjamin Seet, Executive Director of the Biomedical Research Council, A*STAR; His Excellency Bruce Gosper, the Australian High Commissioner to Singapore; Dr Steven Fang, Chief Executive Officer / Founder, Invitrocue Ltd; The Hon Martin Hamilton Smith, Minister for Trade and Investment, South Australian Government; Dr Raj Thampuran, Managing Director, A*STAR; Professor Ng Huck Hui, […]
July 03, 2017 – Invitrocue Limited (ASX:IVQ), a leading healthcare bio-analytic solutions providers, is pleased to announce that it has been granted Human Research Ethics Committee approval to understand a cancer research study with Sydney’s Garvan Institute of Medical Research, to provide further clinical validation of Invitrocue technology for use in personalised real-time screening of […]
22 May, 2017 – Invitrocue (ASX:IVQ) announced today that it will be expanding its cell-based assaying business into skin and wound healing. Invitrocue will develop robust and easy-to-use in vitro assays to assess the safety and effectiveness of consumer antiseptics and over-the-counter (OTC) wound dressing products. Invitrocue has signed a Master Services Agreement with Mundipharma […]
Invitrocue is featured in the first episode of A*STAR TV Business Insider. Watch this broadcast as it tells the story of company, the technology and the people.
Event: Asia Malaria Images Exhibition Opening Talk (Singapore) Venue: The Pod, Level 16, National Library Board, 100 Victoria Street, Singapore 18806 Date: 09 September 2017, Saturday Invitrocue is proud to be an official sponsor of the Asia Malaria Image campaign as part of the Company’s corporate social responsibility initiative. Mark this day and visit […]
Singapore-Australia cooperation on science and technology takes off ; Landing Pad start-up accelerator is latest initiative in strategic partnership The Singapore Government has also boosted co-investment support for promising start-ups specialising in deep-technology, such as medical technology, clean technology and advanced manufacturing and engineering. “Collectively, we expect these initiatives to further boost the local […]
SPEECH BY MR S ISWARAN, MINISTER FOR TRADE AND INDUSTRY (INDUSTRY), AT THE OFFICIAL OPENING OF THE AUSTRALIAN LANDING PAD IN SINGAPORE, ON MONDAY, 13 MARCH 2017, 1040 HRS, AT BASH (79 AYER RAJAH CRESCENT) International connections are critical to facilitating innovation and supporting Singapore’s startup ecosystem. Excerpt:- 8. One example is home-grown local startup […]
SPEECH BY MR LIM HNG KIANG, MINISTER FOR TRADE AND INDUSTRY (TRADE), DURING THE COMMITTEE OF SUPPLY DEBATE UNDER HEAD V (MINISTRY OF TRADE AND INDUSTRY) ON FRIDAY, 3 MARCH 2017 STAYING OPEN AND CONNECTED Excerpt:- 32. In addition, Singapore companies can partner larger companies to venture abroad. Invitrocue, a home grown biotechnology firm that was spun-off from A*STAR, […]
Appendix 4D – Half Yearly Report and Accounts
February 23, 2017 – Invitrocue (ASX: IVQ) is pleased to announce that the company has signed a Collaborative Research Master Agreement with the Garvan Institute of Medical Research. The aim of the collaboration is to provide further medical validation of Invitrocue’s technology for use in personalised real time screening of cancer drugs. It is envisaged […]
Click here to view the results of the AGM 2016.
INTERNATIONAL PRECISION MEDICINE CONVENTION 2016 国际精准医疗大会 December 16-18, 2016 | Beijing, China Booth| email@example.com 16 December 2016, Singapore: InvitroCue Biomedical Service Suzhou is honoured to sponsor this year’s International Precision Medicine Convention. To arrange a time to speak with our scientists, please email us today for a dialogue.
23 November 2016 – Invitrocue (ASX:IVQ) is pleased to announce that Dr. Ramanuj DasGupta, Ph.D will be joining the company as Senior Scientific Director on 1 December 2016. Dr. DasGupta is a highly regarded professor in New York University School of Medicine with more than a decade of experience in cancer research and drug discovery. […]
Biotech CRO InvitroCue Executive director Dr. Steven Fang explains how their technology has disrupted the current clinical trials landscape and the importance of leveraging innovative technologies in meeting future healthcare needs. Interviewer: Could you please introduce to our international readers the main activities of InvitroCue as well as the milestones since its foundation in 2012? […]
October 24, 2016 – Invitrocue (ASX:IVQ) announced a collaboration agreement with the Cancer Therapeutics and Stratified Oncology Group at the Genome Institute of Singapore (GIS), A*STAR. Invitrocue and GIS will jointly conduct a pilot feasibility study using Invitrocue’s cell-based 3D scaffolding technology (Onco-PDO™) to culture colorectal cancer organoids. The aim of the study is to […]
Annual Report Click here to view on ASX. Click here to view on Google Drive.
BioImage Informatics Conference 10-12 October, 2016 October 10-12, 2016 | Breakthrough & Discovery Theatrette, Matrix Level 4, Biopolis, Singapore 19 September 2016, Singapore: Invitrocue Limited (ASX:IVQ) is honoured to be a Title Sponsor in this year’s BioImage Informatics Conference which aims to bring together researchers working in the diverse fields of bioinformatics, image analysis and […]
September 08, 2016 – Invitrocue Limited (ASX: IVQ) has provided the following addendum to the Appendix 4E issued on 31 August for the period ended 30 June 2016. Reverse takeover (RTO) listing on 27 January 2016 During the year, Invitrocue Limited acquired all the shares of Invitrocue Pte Ltd by means of a scrip offer. […]
September 05, 2016 – InvitroCue (ASX:IVQ) has been awarded a tender by the Institute of Bioengineering and Nanotechnology, Agency for Science, Technology and Research (A*STAR), to supply and deliver Hepatocue 96-well plates and 3D-Cellusponge 96-well plates. A*STAR will be utilizing InvitroCue’s technologies to advance research on non-animal approaches to chemical safety testing under an international […]
Preliminary Final Report: Download here.
Appendix 3B – New issue announcement, application for quotation of additional securities and agreement: Download here.
August 22, 2016 – InvitroCue Limited (ASX:IVQ) has announced that its wholly owned subsidiary InvitroCue Biomedical Service Suzhou (“InvitroCue Suzhou”) has signed a Strategic Partnership Agreement with QIAGEN Suzhou Translational Medicine Co. Limited (“QIAGEN Suzhou”). Pursuant to the agreement, InvitroCue Suzhou and QIAGEN Suzhou will jointly accelerate the discovery of biomarkers and translational medicine […]
Escrow Release Click here to download.
July 28, 2016 – InvitroCue (ASX:IVQ), has signed a research collaboration program with Yong Loo Lin School of Medicine, National University of Singapore. The program will focus on InvitroCue’s “3D human liver” to model an in vitro system for the study of chronic Hepatitis B infection. If the program delivers promising data and results by […]
Download the Investment Fact Sheet here.
11 July 2016 – InvitroCue (ASX:IVQ), a leader in advanced bio-analytics, has progressed its technology in modelling multi-organ toxicity by developing a novel assay to detect pancreatic toxicity. The assay is part of a strategic collaboration with InSphero AG (Switzerland), the world’s leading provider of assay-ready 3D microtissues for more predictive drug discovery and development. […]
Advances in Cell-based Screening for Drug Discovery 2016 1. The Use of Genome Editing and iPS Directed Differentiation Systems to Model Human Liver and Pancreatic Disease in vitro (by Dr. Marcus Yeo, Chief Executive Officer, DefiniGEN) Yeo will be overviewing the use of CRISPR gene-editing in combination with induced Pluripotent (iPS) cell differentiation platforms […]
Download the Investor Presentation translated in Simplified Mandarin. Refer to the announced English version herein.
May 24, 2016 – InvitroCue (ASX:IVQ), a leader in advanced bio-analytics, has today announced that the results of the Company’s 3D Culture System for growing stem cell derived hepatocytes have been published in the May print and web editions of Molecular Pharmaceutics (Mol. Pharmaceutics). Mol. Pharmaceutics is an official peer-reviewed online scientific journal which focuses […]
May 20, 2016 – InvitroCue (ASX:IVQ), a leader in advanced bio-analytics, has today announced the appointment of leading experts to its newly formed Scientific and Medical Advisory Board (“SAB”). The SAB will guide the company in a broad range of activities including in vitro cell-based assays, patient-derived organoids, digital pathology and medical imaging. “We are […]
Download the Investor Presentation available on Google Drive and ASX.
May 16, 2016 – InvitroCue (ASX:IVQ), a leader in advanced bio-analytics, announces today a key initiative on Malaria to identify and evaluate new drug targets to tropical infectious diseases. Following its successful initiative on leishmaniasis, InvitroCue establishes an open and collaborative strategy that involves integrated partnerships and networks between academic infectious diseases institutes and pharmaceutical […]
May 12, 2016 – InvitroCue (ASX:IVQ), a leader in advanced bio-analytics, announces today that it is planning to enter the oncology testing market for drugs to provide data points in selected solid tumours. Using its revolutionary 3D cell-based technology and proprietary processes, InvitroCue will be able to culture patient derived cancer cells in its laboratories […]
A*STAR Awards 2016 – Award Ceremony Professor Hanry Yu’s Acceptance Speech “It is with great pleasure that I receive the A*STAR Scientist-Entrepreneur Award. Special thanks to A*STAR for selecting me and an enormous salute to all of this year’s nominees each of whom have made incredible contributions to the scientific and biomedical ecosystem in Singapore. This […]
Event Abstract Extracting meaningful data from cell or tissue images reveals novel insights which enables better decision making in the realms of biomarker discovery, disease prognosis and new therapeutic development. This approach creates the need for bespoke, robust quantitative solutions that must generate reproducible and high quality data. In this presentation, we will share with you the recent advances […]
SINGAPORE and RESEARCH TRIANGLE PARK, NORTH CAROLINA USA April 08, 2016 – InvitroCue (ASX:IVQ), the in-vitro cell-based assaying company, and SciKon Innovation Inc. a US-based life sciences company, today announce a strategic technology partnership that will enable InvitroCue to enhance its focus on delivering customer-centric innovation for its high-value biopharmaceutical customers. The agreement will allow […]
SINGAPORE April 08, 2016 – InvitroCue (ASX:IVQ), the in vitro cell-based assaying company, today announce the global launch of its proprietary CellacylTM assay to monitor and screen carboxylated drug compounds for acyl glucuronides in liver-derived cells (hepatocytes), enabling pharmaceutical companies to streamline compound-ranking during the early phases of drug discovery. Cellacyl is a unique in […]
InvitroCue, a Singapore-based biotech company, made its debut on the Australian Securities Exchange (ASX: IVQ) on Jan 27 2016, – just four years after its founding. The company, a spin-off from A*STAR, announced that it had raised an AUD 3.15 Million (SGD3.17 Million) on the ASX through a reverse takeover. On March 1st, 2016, they […]
09 March 2016 – InvitroCue Pte Ltd (“IVQ” Singapore), together with London School of Hygiene & Tropical Medicine (London), recently signed an Agreement under which they started a collaboration using 3D in vitro technologies to establish leishmania spp. infection in vitro models. These technologies, when integrated, could offer a novel model for the in vitro […]
Featured on The Edge Enterprise, The Week of 07 March 2016 Biotech entrepreneur Dr Steven Fang is no stranger to the start-up scene … Fang recently listed bio-analytics firm InvitroCue on the ASX, just four years after the company was founded. “What we’re doing today breaks almost all records. We took four years to build […]
SINGAPORE and CHINA – March 05, 2016 – InvitroCue Pte Ltd and InvitroCue Biomedical Service Suzhou, a wholly owned subsidiary, today jointly announced the expansion of a cell-based laboratory facility in Suzhou to enhance the company’s current service offerings, and to meet current and future growth of the drug development in China. The expansion is […]
Insight to InvitroCue’s Success – from Invention to IPO February 23, 2016 On Jan 27 2016, local biotech company InvitroCue made its debut on the Australian Securities Exchange (ASX: IVQ) – just four years after its founding. The company, a spin-off from A*STAR, just announced that it had raised an AUD 3.15 Million (SGD3.17 […]
Society of Toxicology 55th Annual Meeting and ToxExpo™ March 13-17, 2016 | New Orleans Ernest N. Morial Convention Center , LA Booth #1653| firstname.lastname@example.org 15 February 2016, Singapore: Invitrocue Limited (ASX:IVQ) is honoured to participate in this year’s 55th Annual Meeting. 2016 promises to be an exciting year for InvitroCue. In only our second year of participation, […]
15 February 2016 – InvitroCue Pte Ltd (“IVQ” Singapore), together with TNO (the Netherlands), and Takara Bio Europe AB (Sweden), recently signed an Agreement under which they started a collaboration using different technologies to develop a model of non-alcoholic steatohepatitis (NASH). This collaborative project is part of TNO’s Early Research Program ‘Organ on-a-chip’, for which they […]
Featured on Singapore News & Top Stories – The Straits Times 05 Feb 2016 By Lin Yangchen The liver is an important organ in drug testing because all drugs pass through it to be detoxified, a process that reduces or removes harmful substances from the body. By constructing a microscopic 3D scaffold to cultivate liver cells […]
Q How did InvitroCue come about? A (Dr Fang) Many of the technologies that InvitroCue is commercialising today were developed by Professor Yu and his team, who are also working for the company now in its effort to take them to market. The development process took about six to seven years, in collaboration with A*Star, […]
At Friday’s forum, National Cancer Centre Singapore also signed a separate agreement with local bioanalytics firm InvitroCue. They will be working on a study of 100 patients from at least five countries to try and better understand cancer disease patterns and how they relate to an individual person’s genetic data. Source: http://www.straitstimes.com/singapore/health/regional-liver-cancer-registry-to-be-set-up
CLEVELAND, OHIO and SINGAPORE – February 01, 2016 – ImageIQ, an innovative Imaging Software and Contract Research Organization supporting preclinical research and clinical trials, announced today an agreement with InvitroCue (“IVQ”), a Singapore-based provider of biomedical quantitative image analytic products and services, to enhance and accelerate preclinical research through the use of cloud-based image analysis […]
全球肝癌病人 80% 在亚洲地区 (Picture from Left to Right) A/Prof Toh Han Chong Deputy Director NCCS, Prof Pierce Chow Senior Consultant Surgeon NCCS and Dr Steven Fang Executive Director IVQ at the MOU Signing Ceremony held on 29 Jan 2016. 《新明日报》刊。 Source： http://www.nccs.com.sg/Newsroom/MediaReleases/2016MediaReleases/Pages/29Jan2016_1.aspx
28 Jan 2016 The Business Times By Claire Huang SUCCESS stories in the Singapore life sciences sphere are few and far between, but InvitroCue, which targets profitability in seven years, could light the way for other homegrown biotechnology firms seeking to get on the global stage. The biotech firm, a spin-off from the Agency for […]
National Cancer Centre Singapore (NCCS) has signed a Memorandum of Understanding (MOU) with InvitroCue Pte Ltd (IVQ) to collaborate on research in the development of applications that will improve treatment outcomes in primary liver cancer or Hepatocellular Cacinoma (HCC). This translational and clinical research in Radiomics is an initiative that will move precision medicine into clinical […]
MOU Signing Ceremony between InvitroCue and Swiss InSphero and Technology Sharing Session On 8th April, 2015, the technology sharing session entitled “Cell Modeling and Analysis Method for Drug Research” was held at NUS (Suzhou) Research Institute. As one of the activities of Singapore-China (Suzhou) Innovation Centre’s NUSRI International Technology Commercialisation platform, the platform steadily supports […]